{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14","value":"220"},{"groupId":"OG001","spread":"53","value":"275"},{"groupId":"OG002","spread":"55","value":"528"},{"groupId":"OG003","spread":"46","value":"1040"},{"groupId":"OG005","spread":"45","value":"1250"},{"groupId":"OG006","spread":"27","value":"2680"},{"groupId":"OG007","spread":"48","value":"3080"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated as there were only two participants. Individual values reported: 3760 ng/mL;1630 ng/mL.","groupId":"OG008","spread":"NA","value":"NA"},{"groupId":"OG009","spread":"17","value":"5130"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"486"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received Selpercatinib 20 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG000","title":"Phase 1: 20 mg Selpercatinib QD"},{"description":"Participants received Selpercatinib 20 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG001","title":"Phase 1: 20 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 40 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG002","title":"Phase 1: 40 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 60 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG003","title":"Phase 1: 60 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 160 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG004","title":"Phase 1: 160 mg Selpercatinib QD"},{"description":"Participants received Selpercatinib 80 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG005","title":"Phase 1: 80 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG006","title":"Phase 1: 120 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG007","title":"Phase 1: 160 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG008","title":"Phase 1: 200 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG009","title":"Phase 1: 240 mg Selpercatinib BID"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All Participants who received at least 1 or more doses of selpercatinib and had PK evaluable data for this outcome.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 hours post dose (cycle length = 28 days)","title":"Phase 1: Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}